Business Overview: Chicago Atlantic BDC, Inc. (NASDAQ: LIEN)

---

Executive Summary

Chicago Atlantic BDC, Inc. is an externally managed, closed-end specialty finance company that has elected to be treated as a business development company (BDC) under the Investment Company Act of 1940, and as a regulated investment company (RIC) for tax purposes. Incorporated in Maryland in 2021 and listed on Nasdaq since February 2022, the company was renamed and changed its ticker to LIEN in October 2024 after acquiring a loan portfolio from an affiliated private vehicle, Chicago Atlantic Loan Portfolio, LLC.

Chicago Atlantic BDC is managed by Chicago Atlantic BDC Advisers, LLC, part of the broader Chicago Atlantic Group lending platform. Its defining characteristic — and the reason it matters within the BDC universe — is that it is the only publicly traded BDC built primarily around cannabis lending, a segment most traditional banks and many generalist private lenders avoid because cannabis remains federally illegal in the United States. As of mid-2025, the portfolio stood at roughly $307.5 million across 33 portfolio companies, with net asset value of about $301.8 million, or $13.23 per share.

---

1. Core Business Model & How They Work

Chicago Atlantic BDC earns money the way most BDCs do — by borrowing and raising equity at a lower cost than the yields it earns lending to its portfolio companies — but it operates in a specific, underserved niche shaped by cannabis's unusual legal status.

[ Capital Raised (Equity + $100M Revolving Credit Facility) ] ⟹ [ Originate Senior-Secured Loans to Niche Borrowers ] ⟹ [ Collect Interest/Fees (Avg. ~16.1% Gross Yield) ] ⟹ [ Distribute as RIC Dividends / Reinvest ]

Key Operational Drivers

1. Regulatory-Gap Lending: Because federally regulated banks are generally unwilling to lend directly to cannabis operators (even in states where cannabis is legal), cannabis companies face a persistent shortage of traditional debt capital. Chicago Atlantic fills that gap, which is why its loans carry a 16.1% gross weighted-average yield — well above the ~11.8% average for public BDCs generally, the ~8.8% U.S. leveraged loan index, and the ~7.3% U.S. high-yield index.
2. Senior-Secured, First-Lien Focus: 100% of the company's debt investments are senior secured, generally first lien, which provides downside protection relative to unsecured or junior lending strategies.
3. Platform-Driven Origination: The Chicago Atlantic platform has closed more than $2.8 billion in loans across 100+ cannabis transactions since inception, and management estimates the platform holds roughly 18% share of the U.S. cannabis debt market — a scale and relationship advantage within a narrow niche that is difficult for a new entrant to replicate quickly.
4. Diversification Beyond Cannabis: Roughly 22% of the portfolio sits outside cannabis, in growth & technology finance, esoteric and asset-based lending, and liquidity/event-driven financing — a deliberate hedge against concentration risk in a single, federally restricted industry.

---

2. Investment Verticals

                    ┌─────────────────────────────┐
                    │   Chicago Atlantic BDC       │
                    └──────────────┬──────────────┘
                                   │
        ┌──────────────────────────┼──────────────────────────┐
        │                          │                          │
┌───────▼────────┐        ┌────────▼────────┐        ┌────────▼────────┐
│    Cannabis     │        │ Growth & Tech /  │        │  Liquidity       │
│   (~78% of      │        │ Esoteric/Asset-  │        │  Solutions       │
│   portfolio)    │        │ Based Lending    │        │  (Event-driven)  │
│                  │        │ (~22% combined)  │        │                  │
└─────────────────┘        └──────────────────┘        └──────────────────┘

• Cannabis (core focus, ~78% of fair value): First- and second-lien loans and limited equity positions in private, state-licensed cannabis operators generating at least half their revenue or profit from cannabis.
• Growth & Technology Finance: Lending to established, high-growth software, hardware, and e-commerce companies, often alongside significant equity capital from sponsors.
• Esoteric & Asset-Based Lending: Secured lending to cash-flow-positive but non-standard borrowers (regulatory, reputational, or idiosyncratic risk profiles), collateralized by receivables, equipment, or real estate.
• Liquidity Solutions: Event-driven financing tied to M&A, refinancings, and dividend recapitalizations.

---

3. Competitive Landscape

• Traditional commercial banks: Generally the largest pool of lending capital in the economy, but largely absent from direct cannabis lending due to federal illegality, banking-secrecy, and reputational concerns — this absence is the core of Chicago Atlantic's opportunity.
• Other cannabis-focused specialty lenders (e.g., Advanced Flower Capital): A small set of direct peers compete for the same underserved cannabis borrower base; Chicago Atlantic differentiates on its platform's origination scale ($2.8B+ closed since inception) and underwriting experience.
• Generalist middle-market BDCs (e.g., Ares Capital, Main Street Capital): Much larger, lower-cost-of-capital lenders that mostly avoid cannabis given regulatory risk, but compete directly in Chicago Atlantic's non-cannabis verticals (growth/tech, asset-based lending).
• Private equity and private credit funds: Broader competition for lower middle-market deal flow; the company explicitly states it does not try to win deals purely by undercutting rates, instead competing on speed, flexibility, and relationship depth.

---

4. Strategic Strengths & Risks

Strengths

• Regulatory moat: Federal cannabis illegality keeps the largest, cheapest sources of capital (banks) out of the market, letting Chicago Atlantic earn structurally higher risk-adjusted yields (16.1% gross) than a comparable loan would command in a fully banked industry.
• Platform scale within a narrow niche: An estimated ~18% share of the U.S. cannabis debt market and a deep deal pipeline (reviewing ~$732 million of potential investments at the time of its 2025 10-K) gives it origination advantages smaller or newer cannabis lenders lack.
• Senior-secured, floating-rate book: 100% senior secured debt and roughly 76.3% floating-rate exposure (nearly half already at interest-rate floors) provide real structural downside protection.

Risks

• Portfolio concentration: The three largest positions represent roughly 17%, 12%, and 10% of fair value — a meaningful concentration risk in an industry where individual operators can face state licensing, pricing, or liquidity shocks.
• Regulatory change is a double-edged sword: Federal cannabis rescheduling or broader legalization — often framed as a positive catalyst for the cannabis industry — could ultimately invite traditional banks into the space, eroding the very yield premium that makes Chicago Atlantic's model attractive.
• Underlying industry fragility: Many cannabis operators remain thinly capitalized and sensitive to state-level pricing compression, making credit losses a persistent risk even with senior-secured structuring.
• Leverage and refinancing risk: The company's $100 million revolving credit facility (closed in 2025) introduces leverage that could amplify losses if portfolio credit quality deteriorates.

---

5. Financial Overview

---

6. Summary Conclusion

Chicago Atlantic BDC's business is, in effect, a bet that cannabis will remain federally restricted long enough for it to keep earning outsized, senior-secured lending yields in a market most traditional capital avoids. Its platform scale and underwriting experience give it a real edge over smaller cannabis-focused lenders today, but the company's biggest long-term risk is success breeding competition: any move toward federal cannabis banking normalization would likely compress the very yield premium that defines its moat, even as it would reduce credit risk across its borrower base.